Tech Company Financing Transactions
Cerevance Funding Round
Cerevance, operating out of Boston, raised $20 million from Dementia Discovery Fund, Double Point Ventures and Gates Frontier Fund.
Transaction Overview
Company Name
Announced On
5/12/2026
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series C
Investors
Dementia Discovery Fund (Tetsuyuki Maruyama)
GV (David Schenkein)
Proceeds Purpose
Proceeds are expected to fund the company's operations into mid-2027, supporting completion of the ARISE trial and continued advancement of Cerevance's pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Marina Park Dr. 1410
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Undisclosed
Website
Email Address
Overview
Cerevance is a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Brad Margus
Chief Financial Officer
Robert Middlebrook
Chief Scientific Officer
Mark Carlton
Chief Scientific Officer
Nathaniel Heintz
Vice President
Roland Bürli
Vice President
Lee Dawson
Vice President
David Margolin
VP - Bus. Development
Ted Hibben
Browse more venture capital transactions:
Prev: 5/12/2026: Heaviside Industries venture capital transaction
Next: 5/12/2026: n8n venture capital transaction
Share this article
Where The Data Comes From
We do our best to document tech company VC transactions. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs